Drug Search Results
More Filters [+]

ASP-5878

Alternative Names: asp-5878, asp5878, asp 5878
Latest Update: 2023-09-12
Latest Update Note: News Article

Product Description

ASP5878 is a selective small-molecule inhibitor of fibroblast growth factor receptors (FGFRs).

Mechanisms of Action: FGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ASP-5878

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

5878-CL-0101

P1

Completed

Oncology Solid Tumor Unspecified

2017-07-19

41%

Recent News Events